Last reviewed · How we verify
NCT06816836: MUSLES
Measuring Ultrasound Guided Skeletal Muscle Mass of Lower Extremity as a Predictor of Post-Operative Length of Stay in Exploratory Gynae-oncology Surgeries
trial testing Bed Side ultrasound guided muscle mass estimation of lower extremity in Gynecologic Cancer in 320 participants. Currently enrolling.
30 September 2027
Quick facts
| Lead sponsor | Tata Medical Center |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 320 |
| Start date | 1 April 2025 |
| Primary completion | 30 September 2027 |
| Estimated completion | 30 September 2027 |
| Sites | 1 location across India |
Drugs / interventions tested
- Bed Side ultrasound guided muscle mass estimation of lower extremity
Conditions studied
- Gynecologic Cancer — all drugs for Gynecologic Cancer →
- Frailty — all drugs for Frailty →
- Sarcopenia — all drugs for Sarcopenia →
Sponsor
Tata Medical Center
Who can join
Adults 50 to 99, female only, with Gynecologic Cancer or Frailty. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Increased incidence of Gynae-oncological cancer is observed specifically in women above 50 years of age. Sarcopenia (a progressive and generalized loss of skeletal muscle mass, quality, and strength) is considered a reliable indicator of frailty, a poor prognostic factor in these patients. Various frailty scores and measurement of psoas muscle mass are time consuming, can't be done in patients unable to walk and altered mental status. The investigators wanted to evaluate if bedside ultrasound guided skeletal muscle measurement, as a measure of sarcopenia, can be used to predict post operative length of stay.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06816836
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gynecologic Cancer
Currently open trials in the same condition.
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07408349 — Guided Imagery of the Gynecological Cancer · NA · recruiting
- NCT07447050 — Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial · Phase 2 · recruiting
- NCT07173101 — Clinical Investigation of the Effects of Semiconductor Embedded Therapeutic Garments on Cancer-related Cognitive Impairm · Phase 2 · recruiting
- NCT07166042 — Guided Meditation During Radiation Therapy for Breast and Gynecological Malignancies · Phase 3 · recruiting
Other Tata Medical Center trials
Trials by the same sponsor.
- NCT06536699 — Trial Comparing Avg. Global Qual of Lifescore in Hypo Frac. RT vs Conv. Frac. in H&N Cancers · NA · not yet recruiting
- NCT05158907 — Patient Reported Scale vs CTCAE Grading: A Prospective Comparator Study · NA · suspended
- NCT03788213 — One Week Versus Three Week in Adjuvant Radiotherapy in Breast Cancer · NA · recruiting
- NCT04249895 — Comprehensive Digital Archive of Cancer Imaging-Radiation Oncology( CHAVI-RO ) · completed
- NCT03669497 — Hypo-Fractionated Radiotherapy in Breast Cancer · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06816836 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tata Medical Center
- Last refreshed: 29 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06816836.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing